Method for improving the specific effector function of single-chain antigen-recognizing genetic constructs (scARC) through murinization thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 28, 2016
Grant Date -
Jun 10, 2010
app pub date -
Aug 31, 2007
filing date -
Sep 4, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a method for producing a cell line expressing a stabilized functional single chain-antigen-recognizing genetic construct (scARC), comprising a genetic construct of the human scARC to be expressed, comprising the domains huV1/2—Li-huV2/1—C4/3 and a genetic construct comprising the corresponding hetero-/(homo-)dimeric domain C3/4, containing xenogenic, in its special case murine amino acid exchanges in the domains C4/3 and C3/4, wherein co-expression of the genetic constructs of the scARC-fragments occurs through the cell. Preferably, the scARCs are single chain-TCRs (scTCRs) or antibody-scFv-fragments, which further preferably recognize tumor associated peptide antigens (TAA). The present invention further relates to a gp100-protein-specific T-cell response mediated α/β T-cell receptor rationally mutated by means of the method of the present invention and its uses.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully